AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 7 - (NewsRx.com & NewsRx.net) -- Adenylate cyclase toxin (ACT) antibody response was low in patients who experienced failed Bordetella pertussis immunization.
According to recent research from the United States, "Presence of antibody to adenylate cyclase toxin (ACT) has been noted following Bordetella pertussis infection. Because ACT is not presently in any acellular pertussis vaccines, it has been considered as a possible antigen to use in B. pertussis diagnostic enzyme-linked immunosorbent assay (ELISA) studies."
"We determined antibody to B. pertussis ACT by ELISA and Western blot tests in serum samples obtained from unvaccinated children, from children vaccinated with several diphtheria and tetanus toxoid vaccines (DTP vaccines), from children vaccinated with vaccines containing acellular pertussis components in combination with diphtheria and tetanus toxoids (DTaP vaccines), and from children and adults with pertussis," reported James D. Cherry at the University of California-Los Angeles in the U.S. and collaborators in the U.S., U.K., and Switzerland. "Primary infections with either B. pertussis or Bordetella parapertussis stimulated a vigorous antibody response to ACT."
"In contrast, patients in whom DTP and DTaP vaccines failed ...
Source: HighBeam Research, ACT antibody response low after failed pertussis vaccination.